Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 8:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 153 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Breathing, Mouth Clear all
Completed Phase 3 Interventional Results available

Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®

NCT01694771
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Tiotropium, Placebo matching Olodaterol, Olodaterol
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
1,134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
90
States / cities
Florence, Alabama • Jasper, Alabama • Phoenix, Arizona + 79 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2014 · Synced Oct 8, 2026, 8:27 AM EDT
Completed Not applicable Interventional Results available

Oral Suction Intervention to Reduce Aspiration and Ventilator Events: NO-ASPIRATE

NCT02284178
View directory record Official record
Conditions
Respiratory Failure
Interventions
Enhanced oropharyngeal suction, Usual Care
Other
Lead sponsor
University of Central Florida
Other
Eligibility
18 Years and older
Enrollment
513 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Aug 15, 2019 · Synced Oct 8, 2026, 8:27 AM EDT
Completed Phase 3 Interventional

A Clinical Trial Assessing the Impact of the Availability of Inhaled Insulin on Glucose Control

NCT00134147
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Inhaled Insulin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
35 Years to 80 Years
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
18
States / cities
La Jolla, California • San Diego, California • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2008 · Synced Oct 8, 2026, 8:27 AM EDT
Completed No phase listed Observational

Evaluating Instrumentation for Dental Devices Used in Treating Sleep Apnea

NCT02056327
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
A novel monitoring suite of sensors will be inserted into the standard oral device.
Device
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
21 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Mar 27, 2014 · Synced Oct 8, 2026, 8:27 AM EDT
Not yet recruiting Phase 4 Interventional Accepts healthy volunteers

Novel Method for Removal of Orally Deposited Inhaled Fluticasone Propionate

NCT07664527
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone Propionate, Water Mouthwash, EVOOW Mouthwash
Drug · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 8, 2026, 8:27 AM EDT
Completed Phase 1 Interventional

Pharmacokinetic Study of CVT-301 (Levodopa Inhalation Powder)

NCT03887884
View directory record Official record
Conditions
Parkinson's Disease
Interventions
CVT-301, Sinemet
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
30 Years to 85 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
5
States / cities
Long Beach, California • Hallandale, Florida • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2019 · Synced Oct 8, 2026, 8:27 AM EDT
Completed Phase 2 Interventional Results available

A Clinical Trial to Evaluate the Safety and Efficacy in Subjects With Chronic Cough

NCT05392192
View directory record Official record
Conditions
Chronic Cough
Interventions
ADX-629, Placebo
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
14
States / cities
San Diego, California • San Jose, California • Hollywood, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2025 · Synced Oct 8, 2026, 8:27 AM EDT
Completed Phase 3 Interventional Results available

Characterization of 24-hour Lung Function Profiles of Inhaled Tiotropium + Olodaterol Fixed Dose Combination in Patients Suffering From Chronic Obstructive Pulmonary Disease

NCT01559116
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
tiotropium + olodaterol, tiotropium, olodaterol, Placebo, Respimat
Drug · Device
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
4
States / cities
Jasper, Alabama • Easley, South Carolina • Greenville, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2015 · Synced Oct 8, 2026, 8:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Assess the Bioavailability and to Compare the Pharmacokinetics of AZD7594 Inhaled Via Monodose Inhaler and Multiple-dose Dry Powder Inhalers (DPI) or Pressurized Metered-dose Inhaler (pMDI) in Healthy Male Subjects

NCT02648438
View directory record Official record
Conditions
Asthma, Chronic Obstructive Pulmonary Disease (COPD)
Interventions
AZD7594 Solution for infusion (150 μg intravenous formulation), AZD7594 Oral suspension (1200 μg oral formulation), AZD7594 Inhalation powder (400 μg) by DPI Device 1 (monodose inhaler), AZD7594 Inhalation powder (400 μg) by DPI device 2 (multiple-dose inhaler), AZD7594 Pressurized inhalation suspension (400 μg) by pMDI
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 15, 2017 · Synced Oct 8, 2026, 8:27 AM EDT
Completed Early Phase 1 Interventional

ETCare: Safety and Preliminary Efficacy Trial

NCT01688440
View directory record Official record
Conditions
Respiratory Distress Syndrome, Newborn
Interventions
#1 Respiratory Care Solution
Other
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
2
States / cities
Ogden, Utah • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 19, 2012 · Synced Oct 8, 2026, 8:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Oral Hymecromone and Hyaluronan Synthesis

NCT02780752
View directory record Official record
Conditions
Healthy, Respiratory Disease
Interventions
hymecromone
Drug
Lead sponsor
Paul Bollyky
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jun 16, 2021 · Synced Oct 8, 2026, 8:27 AM EDT
Terminated Phase 3 Interventional Results available

Effects of Oral Levosimendan on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis (ALS): Open-Label Extension

NCT03948178
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Levosimendan
Drug
Lead sponsor
Orion Corporation, Orion Pharma
Industry
Eligibility
18 Years to 120 Years
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
31
States / cities
Phoenix, Arizona • La Jolla, California • Orange, California + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2023 · Synced Oct 8, 2026, 8:27 AM EDT
Completed Phase 3 Interventional

Effect on Glycemic Control of Inhaled Insulin Alone or Added to Dual Oral Therapy After Failure of Dual Oral Therapy.

NCT00370565
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Inhaled Human Insulin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
35 Years to 80 Years
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2000
U.S. locations
37
States / cities
Irvine, California • Long Beach, California • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2007 · Synced Oct 8, 2026, 8:27 AM EDT
Completed Phase 2 Interventional Results available

Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.

NCT03257995
View directory record Official record
Conditions
Asthma
Interventions
Indacaterol maleate, Indacaterol acetate, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
6
States / cities
North Dartmouth, Massachusetts • St Louis, Missouri • Skillman, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 8, 2026, 8:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and PK Parameters of Sodium Nitrite Inhalation Solution in Healthy Subjects

NCT01409122
View directory record Official record
Conditions
Pulmonary Hypertension, Pulmonary Arterial Hypertension
Interventions
15 mg sodium nitrite inhalation solution, 90 mg sodium nitrite inhalation solution, 45 mg sodium nitrite inhalation solution, 120 mg sodium nitrite inhalation solution, 25% MTD sodium nitrite inhalation solution
Drug
Lead sponsor
Aires Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 56 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 9, 2012 · Synced Oct 8, 2026, 8:27 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of 4 Weeks Treatment With Inhaled BI 1744 CL in Patients With COPD.

NCT00452400
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Asthma
Interventions
BI 1744CL
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
409 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
22
States / cities
Birmingham, Alabama • Lakewood, California • Denver, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2014 · Synced Oct 8, 2026, 8:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Caffeine Disposition After Inhalation

NCT02184104
View directory record Official record
Conditions
Healthy
Interventions
Caffeine
Dietary Supplement
Lead sponsor
University of Tennessee
Other
Eligibility
21 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 26, 2017 · Synced Oct 8, 2026, 8:27 AM EDT
Completed Phase 3 Interventional Results available

Tiotropium +Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)

NCT01431287
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
tiotropium + olodaterol, tiotropium, olodaterol, Respimat
Drug · Device
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
2,539 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
38
States / cities
Greer, California • Fort Collins, Colorado • Danbury, Connecticut + 32 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2015 · Synced Oct 8, 2026, 8:27 AM EDT
Completed Phase 3 Interventional Results available

Beraprost-314d Added-on to Tyvaso® (BEAT)

NCT01908699
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Beraprost Sodium 314d Modified Release Tablets, Placebo
Drug
Lead sponsor
Lung Biotechnology PBC
Industry
Eligibility
18 Years to 80 Years
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
69
States / cities
Birmingham, Alabama • Beverly Hills, California • Fountain Valley, California + 55 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Oct 8, 2026, 8:27 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of 2 Doses of Tiotropium Via Respimat Compared to Placebo in Adolescents With Moderate Persistent Asthma

NCT01257230
View directory record Official record
Conditions
Asthma
Interventions
tiotropium Respimat low dose, placebo Respimat, tiotropium Respimat high dose
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
12 Years to 17 Years
Enrollment
398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
8
States / cities
Plymouth, Minnesota • Columbia, Missouri • Cincinnati, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2014 · Synced Oct 8, 2026, 8:27 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

IOA Preventing Occlusal Changes With MAD Use

NCT07103941
View directory record Official record
Conditions
Sleep Related Breathing Disorder, Snoring, Obstructive Sleep Apnea (OSA), Open Bite, Occlusal Changes, Tooth Migration, Posterior Open Bite
Interventions
AM Aligner, Exercise
Device · Behavioral
Lead sponsor
Isabel Moreno Hay
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 8, 2026, 8:27 AM EDT
Completed Phase 3 Interventional Results available

To Evaluate the Effect of Inhaled Medication Together With Exercise and Activity Training on Exercise Capacity and Daily Activities in Patients With Chronic Lung Disease With Obstruction of Airways

NCT02085161
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
placebo to tiotropium + olodaterol, tiotropium +olodaterol, tiotropium
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years to 75 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
3
States / cities
San Diego, California • Torrance, California • Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 6, 2017 · Synced Oct 8, 2026, 8:27 AM EDT
Completed Not applicable Interventional

Increasing Adherence to Oral Appliance Therapy for Obstructive Sleep Apnea

NCT05038215
View directory record Official record
Conditions
Obstructive Sleep Apnea, Adherence, Patient
Interventions
adherence promotion techniques, Routine Care
Behavioral · Procedure
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 3, 2024 · Synced Oct 8, 2026, 8:27 AM EDT
Terminated Phase 3 Interventional Results available

Dexamethasone to Treat Acute Chest Syndrome in People With Sickle Cell Disease

NCT00530270
View directory record Official record
Conditions
Anemia, Sickle Cell
Interventions
Dexamethasone, Placebo
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
5 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
6
States / cities
Sacramento, California • Louisville, Kentucky • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2013 · Synced Oct 8, 2026, 8:27 AM EDT